ARTICLE | Company News
BioBlast Pharma musculoskeletal news
July 11, 2016 7:00 AM UTC
BioBlast is reducing headcount by 8 (40%) to 12 and will focus development on 90 mg/mL IV trehalose (formerly Cabaletta). The cuts include Chief Commercial Officer Paul Firuta, Chief Corporate Development Officer Theresa Stevens and CFO Robert Cook. Colin Foster will depart as president and CEO but will remain a director. Executive Chairman Fredric Price will lead BioBlast’s operations. The company said it expects to realize savings from the restructuring beginning in 2017 but declined to disclose the anticipated amount. ...